Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

SCCHN

- PMLiVE

BMS CEO tackles investor ‘frustrations’ on immuno-oncology

Company faces pressure from competitors in renal cell carcinoma

- PMLiVE

AZ swells immuno-oncology pipeline with Innate deal

Deal gives access to natural killer cell immunotherapy

- PMLiVE

BMS finds a new immunotherapy partner with $12m Compugen deal

Combination with novel antibody targeting PVRIG pathway

Bristol Myers Squibb logo

BMS psoriasis drug hits the mark in phase II

Tyrosine kinase 2 (Tyk2) inhibitors could play major role

- PMLiVE

FDA green lights BMS’ Opdivo for ‘hard-to-treat’ small cell lung cancer

Becomes the first checkpoint inhibitor for this indication

Bristol-Myers Squibb (BMS) building

BMS presses go on Nektar combo pivotal trials, despite data debate

The data isn’t mature enough to give an accurate ORR reading, says companies

- PMLiVE

Immuno-oncology at ASCO: survival data, combinations and new indications

The abstracts reveal heaps of strong contenders in the NSCLC category

- PMLiVE

Morning brief: Herzuma launched in Europe, rare disease status for Orchard candidate and more

A rapid round-up of pharma, biotech and healthcare news

Bristol-Myers Squibb (BMS) building

BMS pulls IDO inhibitor trials as Incyte-prompted rout gathers pace

Suspends enrolment in BMS-986205 trials for NSCLC and head and neck cancer

- PMLiVE

CHMP backs first-line use for AZ’s Tagrisso in lung cancer

AstraZeneca, Roche and Gilead among companies one step closer to approval

Bristol-Myers Squibb (BMS) building

BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer

Data shows the combo can improve survival compared to Pfizer’s Sutent

José Baselga joins BMS’ board of directors

He will serve as a member of the science and technology committee

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links